Related Experiment Video
Updated: Jun 11, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693
Rakesh Kumar1, Stephen J Blakemore, Catherine E Ellis
1Oncology Biology, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA. rakesh.2.kumar@gsk.com
Background:
Inappropriate activation of AKT signaling is a relatively common occurrence in human tumors, and can be caused by activation of components of, or by loss or decreased activity of inhibitors of, this signaling pathway. A novel, pan AKT kinase inhibitor, GSK690693, was developed in order to interfere with the inappropriate AKT signaling seen in these human malignancies. Causal network modeling is a systematic computational analysis that identifies upstream changes in gene regulation that can serve as explanations for observed changes in gene expression. In this study, causal network modeling is employed to elucidate mechanisms of action of GSK690693 that contribute to its observed biological effects. The mechanism of action of GSK690693 was evaluated in multiple human tumor cell lines from different tissues in 2-D cultures and xenografts using RNA expression and phosphoproteomics data. Understanding the molecular mechanism of action of novel targeted agents can enhance our understanding of various biological processes regulated by the intended target and facilitate their clinical development.
Results:
Causal network modeling on transcriptomic and proteomic data identified molecular networks that are comprised of activated or inhibited mechanisms that could explain observed changes in the sensitive cell lines treated with GSK690693. Four networks common to all cell lines and xenografts tested were identified linking GSK690693 inhibition of AKT kinase activity to decreased proliferation. These networks included increased RB1 activity, decreased MYC activity, decreased TFRC activity, and increased FOXO1/FOXO3 activity.
Conclusion:
AKT is involved in regulating both cell proliferation and apoptotic pathways; however, the primary effect with GSK690693 appears to be anti-proliferative in the cell lines and xenografts evaluated. Furthermore, these results indicate that anti-proliferative responses to GSK690693 in either 2-D culture or xenograft models may share common mechanisms within and across sensitive cell lines.
Insights
The AKT inhibitor GSK690693 demonstrates anti-proliferative effects in human tumors by modulating key molecular networks. This study used causal network modeling to reveal how GSK690693 impacts tumor cell proliferation and gene regulation.
Area of Science:
- Oncology
- Molecular Biology
- Computational Biology
Background:
- Aberrant AKT signaling is common in human cancers.
- GSK690693 is a novel pan-AKT kinase inhibitor designed to target this pathway.
- Causal network modeling analyzes gene regulation to understand drug mechanisms.
Purpose of the Study:
- To elucidate the molecular mechanisms of action of GSK690693 using causal network modeling.
- To investigate the effects of GSK690693 on AKT signaling in various human tumor cell lines and xenografts.
Main Methods:
- Utilized causal network modeling on transcriptomic and phosphoproteomic data.
- Evaluated GSK690693 in 2-D cell cultures and xenograft models.
- Analyzed RNA expression and phosphoproteomics data to identify molecular networks.
Main Results:
- Identified four common molecular networks linking GSK690693's inhibition of AKT to decreased proliferation across all tested cell lines and xenografts.
- Observed increased RB1 activity, decreased MYC activity, decreased TFRC activity, and increased FOXO1/FOXO3 activity.
- GSK690693 treatment resulted in significant changes in these molecular networks.
Conclusions:
- The primary effect of GSK690693 is anti-proliferative, impacting cell proliferation and apoptotic pathways.
- Common anti-proliferative mechanisms are shared by GSK690693 across sensitive cell lines and models.
- Understanding these mechanisms aids in the clinical development of targeted AKT inhibitors.
Related Concept Videos
MAPK Signaling Cascades
Amplifying Signals via Enzymatic Cascade
cAMP-dependent Protein Kinase Pathways
GPCRs Regulate Adenylyl Cylase Activity
Two...
PI3K/mTOR/AKT Signaling Pathway
GPCR Desensitization

